Actively Recruiting
Cancer in Inherited Bone Marrow Failure Syndromes
Led by National Cancer Institute (NCI) · Updated on 2026-05-07
4000
Participants Needed
2
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Background: A prospective cohort of Inherited Bone Marrow Failure Syndrome (IBMFS) will provide new information regarding cancer rates and types in these disorders. Pathogenic variant(s) in IBMFS genes are relevant to carcinogenesis in sporadic cancers. Patients with IBMFS who develop cancer differ in their genetic and/or environmental features from patients with IBMFS who do not develop cancer. These cancer-prone families are well suited for cancer screening and prevention trials targeting those at increased genetic risk of cancer. Carriers of IBMFS pathogenic variant(s) are at increased risk of cancer. The prototype disorder is Fanconi's Anemia (FA); other IBMFS will also be studied. Objectives: To determine the types and incidence of specific cancers in patients with an IBMFS. To investigate the relevance of IBMFS pathogenic variant(s) in the carcinogenesis pathway of the sporadic counterparts of IBMFS-associated cancers. To identify risk factors for IBMFS-related cancers in addition to the primary germline pathogenic variant(s). To determine the risk of cancer in IBMFS carriers. Eligibility: North American families with a proband with an IBMFS. IBMFS suspected by phenotype, confirmed by pathogenic variant(s) in an IBMFS gene, or by clinical diagnostic test. Fanconi's anemia: birth defects, marrow failure, early onset malignancy; positive chromosome breakage result. Diamond-Blackfan anemia: pure red cell aplasia; elevated red cell adenosine deaminase. Dyskeratosis congenita: dysplastic nails, lacey pigmentation, leukoplakia; marrow failure. Shwachman-Diamond Syndrome: malabsorption; neutropenia. Amegakaryocytic thrombocytopenia: early onset thrombocytopenia. Thrombocytopenia absent radii: absent radii; early onset thrombocytopenia. Severe Congenital Neutropenia: neutropenia, pyogenic infections, bone marrow maturation arrest. Pearson's Syndrome: malabsorption, neutropenia, marrow failure, metabolic acidosis; ringed sideroblasts. Other bone marrow failure syndromes: e.g. Revesz Syndrome, WT, IVIC, radio-ulnar synostosis, ataxia-pancytopenia. First degree relatives of IBMFS-affected subjects as defined here, i.e. siblings (half or full), biologic parents, and children. Grandparents of IBMFS-affected subjects. Patients in the general population with sporadic tumors of the types seen in the IBMFS (head and neck, gastrointestinal, and anogenital cancer), with none of the usual risk factors (e.g. smoking, drinking, HPV). Design: Natural history study, with questionnaires, clinical evaluations, clinical and research laboratory test, review of medical records, cancer surveillance. Primary endpoints are all cancers, solid tumors, and cancers specific to each type of IBMFS. Secondary endpoints are markers of pre-malignant conditions, such as leukoplakia, serum or tissue evidence of carcinogenic viruses, and bone marrow morphologic myelodyplastic syndrome or cytogenetic clones....
CONDITIONS
Official Title
Cancer in Inherited Bone Marrow Failure Syndromes
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants affected by an IBMFS or family members at risk or carriers of the syndrome
- Equal numbers of male and female probands and family members, except for rare X-linked recessive cases
- All racial and ethnic groups included
- Age range from birth to old age, including grandparents
- Patients diagnosed with Fanconi anemia, Diamond Blackfan anemia, Dyskeratosis congenita, Shwachman Diamond Syndrome, Amegakaryocytic thrombocytopenia, Thrombocytopenia absent radii, Severe Congenital Neutropenia, Pearson Syndrome, or other bone marrow failure syndromes
- Family members include siblings (half or full), biological parents, children, and grandparents of IBMFS-affected subjects
- Patients with sporadic tumors similar to IBMFS-related cancers but without usual risk factors, evaluated and possibly diagnosed with IBMFS
You will not qualify if you...
- Hematologic disorder is acquired, caused by drugs, chemicals, toxins, or viruses without evidence of inherited marrow failure
- Cytopenias caused by autoantibodies, viruses, micronutrient deficiencies, transient erythroblastopenia of childhood, or cyclic neutropenia
- Physical findings assigned to syndromes or causes outside of IBMFS
- Inability or unwillingness of participant or legal representative to understand and sign informed consent
- Unwillingness to allow access to medical records and pathology specimens
- For unaffected family members, no affected individual in the family meeting inclusion criteria
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
National Institutes of Health Clinical Center
Bethesda, Maryland, United States, 20892
Actively Recruiting
2
National Cancer Institute - Shady Grove
Rockville, Maryland, United States, 20850
Actively Recruiting
Research Team
N
NCI Family Study Referrals
CONTACT
L
Lisa J McReynolds, M.D.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here